But the stock's popularity may have driven its price up to the point where it is no longer a good bargain compared with the slightly smaller and less rapidly growing Biogen (NASDAQ:BIIB).As it turns out, Biogen's true value lies in its larger drug-development pipeline as well as its operational efficiency, both of which have laid a strong foundation for the company to be more successful than Vertex in the long term.